Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

clinical trial

Details

Instance of: clinical trial
Start time: September 2020
End time: May 2022
Main subject: antipsychotics, obesity, weight gain, risperidone, olanzapine, schizophrenia
clinical trial phase: phase II clinical trial
maximum age: 65
minimum age: 18
number of participants: 150
research subject recruitment status: not yet recruiting
study type: interventional study
title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)

Nothing in the MetaHistoryBook collection references this item yet.